Latest Bextra Stories
The personal injury law firm of d’Oliveira & Associates has issued an infographic on Stevens Johnson Syndrome, which details potential causes and serious conditions that may result from
New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration (FDA) if the cardiovascular effects of fluid retention had been better understood.
NEW YORK, March 25 /PRNewswire/ -- Grant & Eisenhofer, a leading shareholder and corporate governance law firm, was successful in upholding the admission of testimony against pharmaceutical giant Pfizer by six expert witnesses in a rare securities-related Daubert hearing. U.S.
BOSTON, Oct. 16 /PRNewswire-USNewswire/ -- PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.
Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON, Sept. 2 /PRNewswire-USNewswire/ -- American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc.
The US Department of Justice said pharmaceutical giant Pfizer will pay a record $2.3 billion fine to settle fraudulent marketing of the painkiller Bextra.
WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex.
Pfizer Inc announced today that it has finalized agreements with 33 states and the District of Columbia to resolve claims primarily related to alleged promotional practices for Bextra, a medication Pfizer voluntarily withdrew from the United States market in 2005.
- A political dynamiter.